Literature DB >> 23645100

Serum sclerostin levels following treatment with parathyroid hormone.

S A Polyzos, A D Anastasilakis, E Terpos.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23645100     DOI： 10.1007/BF03347276

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN： 0391-4097            Impact factor:   4.256


× No keyword cloud information.
  8 in total

1.  Circulating fibroblast growth factor-23 increases following intermittent parathyroid hormone (1-34) in postmenopausal osteoporosis: association with biomarker of bone formation.

Authors:  M Sridharan; J Cheung; A E Moore; M L Frost; W D Fraser; I Fogelman; G Hampson
Journal:  Calcif Tissue Int       Date:  2010-09-14       Impact factor: 4.333

2.  Acute decline in serum sclerostin in response to PTH infusion in healthy men.

Authors:  Elaine W Yu; Ruchit Kumbhani; Erica Siwila-Sackman; Benjamin Z Leder
Journal:  J Clin Endocrinol Metab       Date:  2011-08-24       Impact factor: 5.958

3.  The waning of teriparatide effect on bone formation markers in postmenopausal osteoporosis is associated with increasing serum levels of DKK1.

Authors:  Davide Gatti; Ombretta Viapiana; Luca Idolazzi; Elena Fracassi; Maurizio Rossini; Silvano Adami
Journal:  J Clin Endocrinol Metab       Date:  2011-03-02       Impact factor: 5.958

4.  Association of serum sclerostin with bone mineral density, bone turnover, steroid and parathyroid hormones, and fracture risk in postmenopausal women: the OFELY study.

Authors:  P Garnero; E Sornay-Rendu; F Munoz; O Borel; R D Chapurlat
Journal:  Osteoporos Int       Date:  2012-04-14       Impact factor: 4.507

5.  Serum sclerostin levels positively correlate with lumbar spinal bone mineral density in postmenopausal women--the six-month effect of risedronate and teriparatide.

Authors:  S A Polyzos; A D Anastasilakis; C Bratengeier; W Woloszczuk; A Papatheodorou; E Terpos
Journal:  Osteoporos Int       Date:  2011-01-11       Impact factor: 4.507

6.  Bisphosphonate treatment of postmenopausal osteoporosis is associated with a dose dependent increase in serum sclerostin.

Authors:  Davide Gatti; Ombretta Viapiana; Silvano Adami; Luca Idolazzi; Elena Fracassi; Maurizio Rossini
Journal:  Bone       Date:  2011-12-10       Impact factor: 4.398

7.  Effects of parathyroid hormone treatment on circulating sclerostin levels in postmenopausal women.

Authors:  Matthew T Drake; Bhuma Srinivasan; Ulrike I Mödder; James M Peterson; Louise K McCready; B Lawrence Riggs; Denise Dwyer; Marina Stolina; Paul Kostenuik; Sundeep Khosla
Journal:  J Clin Endocrinol Metab       Date:  2010-07-14       Impact factor: 5.958

8.  Serum sclerostin levels decline in post-menopausal women with osteoporosis following treatment with intermittent parathyroid hormone.

Authors:  S Piemonte; E Romagnoli; C Bratengeier; W Woloszczuk; A Tancredi; J Pepe; C Cipriani; S Minisola
Journal:  J Endocrinol Invest       Date:  2012-07-24       Impact factor: 4.256
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.